Atlas Trials

An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder Cancer

Clinical trial NCT03801278 · NO_LONGER_AVAILABLE

Trial details

NCT number
NCT03801278
Sponsor
Five Prime Therapeutics, Inc.
Status
NO_LONGER_AVAILABLE
Study type
EXPANDED_ACCESS
Recurrent Bladder Cancer

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.